180 related articles for article (PubMed ID: 9713009)
1. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
De Boeck K; Smet M; Eggermont E
Pediatr Pulmonol; 1989; 7(3):171-3. PubMed ID: 2508049
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
[TBL] [Abstract][Full Text] [Related]
5. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.
Gold R; Overmeyer A; Knie B; Fleming PC; Levison H
Pediatr Infect Dis; 1985; 4(2):172-7. PubMed ID: 3885181
[TBL] [Abstract][Full Text] [Related]
6. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
McCrae WM; Raeburn JA; Hanson EJ
J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
[TBL] [Abstract][Full Text] [Related]
7. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
Parry MF; Neu HC
J Infect Dis; 1976 Aug; 134 Suppl():S194-7. PubMed ID: 823276
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
Fraser GL; Valenti AJ; Grimes GR; Corbin RP
Drug Intell Clin Pharm; 1985 Oct; 19(10):757-61. PubMed ID: 4053983
[TBL] [Abstract][Full Text] [Related]
10. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
Crozier DN; Khan SR
J Infect Dis; 1976 Aug; 134 Suppl():S187-90. PubMed ID: 823275
[TBL] [Abstract][Full Text] [Related]
11. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Stenvang Pedersen S; Pressler T; Pedersen M; Høiby N; Friis-Møller A; Koch C
Scand J Infect Dis; 1986; 18(2):133-7. PubMed ID: 3518048
[TBL] [Abstract][Full Text] [Related]
12. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Gappa M; Steinkamp G; Tümmler B; von der Hardt H
Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
[TBL] [Abstract][Full Text] [Related]
13. A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis.
Sherwood SJ; Tak C; Bhakta ZN; Packer K; Jacobs H; Liou TG; Young DC
Pediatr Pulmonol; 2024 Jun; 59(6):1740-1746. PubMed ID: 38501330
[TBL] [Abstract][Full Text] [Related]
14. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.
Smith AL; Ramsey BW; Hedges DL; Hack B; Williams-Warren J; Weber A; Gore EJ; Redding GJ
Pediatr Pulmonol; 1989; 7(4):265-71. PubMed ID: 2515523
[TBL] [Abstract][Full Text] [Related]
15. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis.
McCarty JM; Tilden SJ; Black P; Craft JC; Blumer J; Waring W; Halsey NA
Pediatr Pulmonol; 1988; 4(4):201-4. PubMed ID: 3393383
[TBL] [Abstract][Full Text] [Related]
16. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.
Li SC; Bowes G; Ioannides-Demos LL; Spicer WJ; Hooper RE; Spelman DW; Tong N; McLean AJ
J Antimicrob Chemother; 1991 Oct; 28(4):561-8. PubMed ID: 1761450
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Rubio TT; Shapiro C
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
[TBL] [Abstract][Full Text] [Related]
18. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis.
Hjelte L; Malmborg AS; Strandvik B
J Antimicrob Chemother; 1989 Jun; 23(6):885-90. PubMed ID: 2503488
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
MacLusky IB; Gold R; Corey M; Levison H
Pediatr Pulmonol; 1989; 7(1):42-8. PubMed ID: 2505216
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L
J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
